<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20230515058198N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-07-24</date_registration>
      <primary_sponsor>Shiraz University of Medical Sciences</primary_sponsor>
      <public_title>Investigating the effect of piroxicam mesotherapy in the treatment of tennis elbow</public_title>
      <acronym>LET</acronym>
      <scientific_title>Investigation of the effect of mesotherapy with piroxicam in the treatment of tennis elbow in comparison with oral medical therapy in terms of improving pain and function</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-08-01</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>36</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/71349</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patients will be randomly allocated into two groups by Block Randomization Assignment and double blind methods. We will have two lists of 18 patients including the intervention and control groups, at random. For concealment, method of random sequencing is given to another individual who is unaware of the research process. All questionnaires will be completed by an individual unaware of the division of groups, Blinding description: Participant: in this study, we do not have the ability to blind the participant because the participants are aware of receiving each intervention. Clinical care giver: we instruct the caregiver how to complete the questionnaires. This person is not aware of receiving patient’s intervention. Researcher: this study does not have the ability to blind the researcher due to performing both interventions by himself and being aware of receiving the kind of intervention in each group. The outcome assessor of the completed questionnaires is given to an individual who is not aware of the interventions and he/she is asked to determine the level of performance in each subject according to the questionnaires. Data analyzer: questionnaire are finally given to a person to review the information. This person does not know any of the steps of the study and the way of classification in which the interventions performed.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Lateral epicondylitis.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Subcutaneous injection (mesotherapy) of 1 ml piroxicam 20 mg/ml with 1 ml lidocaine 2% is applied in the acupuncture points Lu6, Li10, Li11, Li12 and the maximal tender point of the affected elbow. Mesotherapy is performed in 2 sessions at intervals of one week according to the common and sterile protocol along with lifestyle modification, doing stretching and strengthening exercises of the wrist extensor muscles and using tennis elbow band. The patients have to complete the Visual Analog Scale and Patient-Rated Tennis Elbow Evaluation questionnaires before entering the study and 2 and 4 weeks after intervention. Intervention 2: Control group: Oral naproxen 500 mg twice a day (one every 12 hours) is used for seven days. Oral medical treatment is done along with lifestyle modification, doing stretching and strengthening exercises of the wrist extensor muscles and using tennis elbow band. The patients have to complete the Visual Analog Scale and Patient-Rated Tennis Elbow Evaluation questionnaires before entering the study and 2 and 4 weeks after intervention.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All available data can be shared after making people unidentifiable.

When:
Start access period one year after publishing the results

To whom:
Everyone can access to this information.

Conditions:
If the information in this study helps to improve the science process.

Where to obtain:
Dr. Zahra Zare, 00989173296042, niloofarzare@sums.ac.ir

How to obtain:
After sending the desired message, all authors of the study will be consulted. All information will be sent within a maximum of three weeks if permitted.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Zahra Zare</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>7th floor, unit 52, Imam Hossein dormitory medical science building, 36th alley, Zand Blvd.</address>
        <city>Shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7135744661</zip>
        <telephone>+98 71 3231 5768</telephone>
        <email>niloofarzare@sums.ac.ir</email>
        <affiliation>Shiraz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Zahra Zare</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>7th floor, unit 52, Imam Hossein dormitory medical science building, 36th alley, Zand Blvd.</address>
        <city>Shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7135744661</zip>
        <telephone>+98 71 3231 5768</telephone>
        <email>niloofarzare@sums.ac.ir</email>
        <affiliation>Shiraz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Completing and signing the consent form
Clinical diagnosis of tennis elbow in the form of pain in the external epicondyle region of the humerus bone by applying local pressure and wrist extension against resistance
At least one month has passed since the onset of the patient's symptoms
Having a pain Visual Analogue Scale of at least 4</inclusion_criteria>
      <agemin>20 years</agemin>
      <agemax>60 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Any signs and symptoms of effusion, inflammation, redness and warmth of the affected area
Having uncontrolled diabetes mellitus
Having rheumatic and collagen vascular disorders
Suffering from active cervical radiculopathy, neuropathy or myopathy simultaneously in the upper limbs
Having any type of serious systemic and local infection
History of surgery, trauma, fracture and dislocation in the elbow joint on the affected side, severe deformity in the upper limb
Individuals with bleeding disorders and/or taking anticoagulants
History of allergies and allergic reactions to the medications used
History of significant liver, kidney, gastrointestinal, cerebral and cardiopulmonary disorders, history of gastrointestinal bleeding
History of injections in or around the affected elbow joint in the last three months
History of elbow and upper limb physiotherapy in the last one month
Taking non-steroidal anti-inflammatory drugs (NSAIDs) in the last 48 hours and steroidal anti-inflammatory drugs in the last two weeks
Pregnant women and lactating women
Individuals with cancer
Inability to communicate and complete questionnaires</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>M77.1</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Lateral epicondylitis</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Rehabilitation</i_code>
      <i_code>Rehabilitation</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Subcutaneous injection (mesotherapy) of 1 ml piroxicam 20 mg/ml with 1 ml lidocaine 2% is applied in the acupuncture points Lu6, Li10, Li11, Li12 and the maximal tender point of the affected elbow. Mesotherapy is performed in 2 sessions at intervals of one week according to the common and sterile protocol along with lifestyle modification, doing stretching and strengthening exercises of the wrist extensor muscles and using tennis elbow band. The patients have to complete the Visual Analog Scale and Patient-Rated Tennis Elbow Evaluation questionnaires before entering the study and 2 and 4 weeks after intervention.</i_keyword>
      <i_keyword>Control group: Oral naproxen 500 mg twice a day (one every 12 hours) is used for seven days. Oral medical treatment is done along with lifestyle modification, doing stretching and strengthening exercises of the wrist extensor muscles and using tennis elbow band. The patients have to complete the Visual Analog Scale and Patient-Rated Tennis Elbow Evaluation questionnaires before entering the study and 2 and 4 weeks after intervention.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Upper limb pain. Timepoint: Before intervention, two weeks and four weeks later. Method of measurement: Visual Analogue Scale (VAS); Patient-Rated Tennis Elbow Evaluation (PRTEE).</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Function of patient. Timepoint: Before intervention, two weeks and four weeks later. Method of measurement: Patient-Rated Tennis Elbow Evaluation (PRTEE).</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shiraz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-05-06</approval_date>
        <contact_name>Ethics committee of Shiraz University of Medical Sciences</contact_name>
        <contact_address>7th floor, unit 52, Imam Hossein dormitory medical science building, 36th alley, Zand Blvd. Shiraz Fars Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
